Eliminating residual undifferentiated cells from iPSC-CMs for safer clinical application of iPSCs
| Project/Area Number |
15K10211
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Cardiovascular surgery
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
Masuda Shigeo 大阪大学, 医学系研究科, 特任准教授(常勤) (10396749)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | ヒトiPS細胞 / 造腫瘍性 / 未分化細胞除去 / 分子標的治療薬 |
|---|
| Outline of Final Research Achievements |
Clinical application of iPS-derived cardiomyocytes (iPS-CMs) is considered to be one of the most promising approach to regenerative treatment for severe heart failure. However, its success would largely depend on safety, including prevention of tumor formation (Masuda S, et al. Nature Rev Cardiol. 2014;11:553-4). Here, we demonstrate that BET protein bromodomain antagonist is efficacious in removing residual undifferentiated cells in vitro. In this context, it was revealed that BET protein antagonist functions as a Nanog inhibitor within human iPS cells. Furthermore, co-treatment with BET protein antagonist and CDK inhibitors (CDK9 or CDK1 inhibitor) synergistically eliminated residual undifferentiated cells among human iPS-CMs. These findings imply that combination treatment in vitro with these drugs contributes to molecular-targeted treatment on “human iPS cells”.
|
Report
(4 results)
Research Products
(26 results)
-
[Journal Article] Pivotal role of non-cardiomyocytes in electromechanical and therapeutic potential of induced pluripotent stem cell-derived engineered cardiac tissue.2018
Author(s)
Iseoka H, Miyagawa S, Fukushima S, Saito A, Masuda S, Yajima S, Ito E, Sougawa N, Takeda M, Harada A, Lee JK, Sawa Y.
-
Journal Title
Tissue Eng Part A.
Volume: 24(3-4)
Issue: 3-4
Pages: 287-300
DOI
Related Report
Peer Reviewed / Int'l Joint Research
-
-
-
-
-
-
[Journal Article] Teratocarcinomas Arising from Allogeneic Induced Pluripotent Stem Cell-Derived Cardiac Tissue Constructs Provoked Host Immune Rejection in Mice.2016
Author(s)
Kawamura A, Miyagawa S, Fukushima S, Kawamura T, Kashiyama N, Ito E, Watabe T, Masuda S, Toda K, Hatazawa J, Morii E, Sawa Y.
-
Journal Title
Scientific Reports
Volume: 29
Issue: 1
Pages: 22130-22130
DOI
Related Report
Peer Reviewed / Open Access / Int'l Joint Research
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] DRUG RE-POSITIONING ENABLES ELIMINATION OF UNDIFFERENTIATED CELLS IN CLINICAL APPLICATION OF IPS CELLS.2015
Author(s)
Masuda S, Miyagawa S, Fukushima S, Okimoto K, Ueda Y, Kawaguchi K, Mori D, Kawamura A, Ito E, Sougawa N, Imanishi Y, Saito A, Sawa Y.
Organizer
13th International Society for Stem Cell Research: Annual Meeting
Place of Presentation
Stockholm, Sweden
Year and Date
2015-06-24
Related Report
Int'l Joint Research
-
-
-
[Book] 日本再生医療学会雑誌2017
Author(s)
増田茂夫、宮川繁、澤芳樹
Total Pages
1
Publisher
メディカルレビュー社
ISBN
9784779219993
Related Report
-
-
-
